SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance

Sgherza, Nicola; Gennaro, Daniela Di; Curci, Paola; Rizzi, Rita; Roccotelli, Daniela; Croce, M; Avantaggiato, M; Ruga, L.; Strafella, Vanda; Vitucci, Angelantonio; Palma, Antonio; Rossi, Alessia; Troiano, T; Larocca, Angela Maria Vittoria; Chironna, Maria; Tafuri, Silvio; Albano, Francesco; Musto, Pellegrino

doi:10.1097/hs9.0000000000000800

Cited by 2 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the context of SARS-CoV-2 vaccination, studies have shown that the response in neutralizing antibodies in fully vaccinated patients with precursor stages of multiple myeloma (MM) was comparable to that of healthy controls and asymptomatic patients [12]. Another study investigated the efficacy of anti-SARS-CoV-2 vaccines in MGUS patients and found that fully vaccinated individuals had a similar likelihood of SARS-CoV-2 infection compared to unvaccinated MGUS patients, but experienced improved COVID-19 outcomes [13].…”

Section: Serological Responses In Mgus and Myeloma Patients Post Infe...mentioning

confidence: 99%

Clinical Features and Risk Stratification of Multiple Myeloma Patients with COVID-19

Zheng

Bennett

et al. 2023

Cancers

View full text Add to dashboard Cite

SARS-CoV-2 infection often results in a more severe COVID-19 disease course in multiple myeloma (MM) patients compared to immunocompetent individuals. The aim of this report is to summarize the clinical features of the MM patients with COVID-19 and the impact of MM treatment on outcomes to guide risk stratification and ensure the appropriate management of the patients. Serological responses in MM patients post-infection or -vaccination are also reviewed to better understand the strategy of prevention. Along with reports from the literature, we presented findings from a retrospective analysis of the clinical characteristics and outcomes of COVID-19 infection in MM patients in our institution. Study population includes 34 MM patients with a median age of 61 (range: 35–82 years) who tested positive for SARS-CoV-2 between 1 March 2020–15 August 2021. We examined the effect of chemotherapy, the benefit of neutralizing monoclonal antibody (Bamlanivimab) and the impact of anti-CD38 antibody (daratumumab) on the hospitalization and mortality of the patients, as well as the efficacy of native antibody production. Our results showed that MM patients have increased hospitalization and mortality rates from COVID-19 compared with that of general population, especially those on active chemotherapy. Advanced age, high-risk myeloma, renal disease, and suboptimal disease control are independent predictors of adverse outcomes. The use of daratumumab does not increase the disease severity/hospitalization or the post-infection/vaccination seropositivity of SARS-CoV-2. The neutralizing antibody decreases overall mortality. Evidence from the current study and previous publications suggest that testing of neutralizing antibody post-SARS-CoV-2 vaccination in MM patients may be needed in reducing COVID-19 risk.

show abstract

Section: Serological Responses In Mgus and Myeloma Patients Post Infe...mentioning

confidence: 99%

Clinical Features and Risk Stratification of Multiple Myeloma Patients with COVID-19

Zheng

Bennett

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

Humoral immune response after anti-SARS-CoV-2 vaccine “booster” dose in patients with monoclonal gammopathy of undetermined significance (MGUS)

Sgherza

Curci

Rizzi³

et al. 2023

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

show abstract

SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance

Cited by 2 publications

References 13 publications

Clinical Features and Risk Stratification of Multiple Myeloma Patients with COVID-19

Clinical Features and Risk Stratification of Multiple Myeloma Patients with COVID-19

Humoral immune response after anti-SARS-CoV-2 vaccine “booster” dose in patients with monoclonal gammopathy of undetermined significance (MGUS)

Contact Info

Product

Resources

About